Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Texas company is planning to sell 30,000 at-home sample collection kits for COVID-19 testing beginning on 23 March.
Latest From Deals
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
At the LSX World Congress in London, leaders from Medtronic, Johnson & Johnson and Olympus discussed the evolving medtech mergers and acquisitions landscape, the big opportunity in robotic surgery and the impacts on innovation of the forthcoming EU Medical Device Regulation.
More investor suits were brought against life sciences companies in 2019 than in any of the past five years, according to a new report from law firm Dechert LLP. The increase continues a trend that has seen the number of such suits more than double since 2014.
2019 was a robust year for device fundraising and the trend will continue this year according to Nooman Haque, managing director of life sciences and healthcare at Silicon Valley Bank’s UK branch. However, medtech companies without a data proposition may find themselves struggling to compete.
Illumina Inc. has agreed to pay $98m to terminate its merger agreement with Pacific Biosciences of California Inc. following opposition from antitrust regulators in the US and UK. See what Illumina CEO Francis deSouza said about it here.
Illumina had planned to acquire Pacific Biosciences to add the company's “long-read” gene sequencing systems to Illumina's own range of "short-read" technologies. However, the UK’s Competition and Markets Authority and the US Federal Trade Commission concluded that the deal would significantly reduce competition in the DNA sequencing market.
Laborie Medical Technologies has inked a $525m deal to buy obstetrics device maker Clinical Innovations. The acquisition adds a suite of neonatal and fetal care devices to Laborie’s existing obstetrics portfolio.
Johnson & Johnson is acquiring the remaining stake in Verb Surgical from Verily following a four-year partnership. The transaction is expected to close in the first half of 2020.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.